Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Immune-Onc Therapeutics

Request full access

Developing a novel class of myeloid checkpoint inhibitors

Palo Alto, United StatesFounded 2016Biotech & Life Sciences

About Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage startup operating in the healthcare sector, specifically in the field of cancer immunotherapy. The company is pioneering a new class of treatments known as myeloid checkpoint inhibitors, which are believed to be the next big thing in cancer immunotherapy. These inhibitors work by targeting immune suppressive pathways, potentially transforming the current treatment approaches for both blood cancers and solid tumors.

Immune-Onc's business model revolves around research and development, with a focus on creating a portfolio of these novel inhibitors. The company collaborates with scientists, academic institutions, and non-profit cancer organizations to discover and develop new immunomodulatory approaches to cancer treatment. Their clients are primarily patients suffering from various types of cancer who could benefit from immunotherapy.

The company operates in the biopharmaceutical market, a sector characterized by high research and development costs, long product development cycles, and a complex regulatory environment. Immune-Onc generates revenue through the development and eventual commercialization of its innovative cancer treatments. The company's efforts are supported by investors with significant industry experience, who are committed to making the company's vision a reality for patients.

Source: Dealroom company data

At a glance

Status
Operational
Employees
13
Open positions
None listed
Dealroom signal
65.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2023 $25M $365M The Leukemia & Lymphoma Society · Proxima Ventures · WuXi Biologics · TriWise Capital ↗
SERIES BOther financing Apr 2021 $73M $292M NLVC · The Leukemia & Lymphoma Society · Sphera Funds Management · Vivo Capital —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Immune-Onc Therapeutics website traffic

Latest recorded traffic for Immune-Onc Therapeutics is 2.6K monthly website visits, up 44.4% over the last three months. Immune-Onc Therapeutics's team declined 13.3% over the past year.

Latest monthly visits2.6K 3-month web change+44.4% 1-year team growth-13.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Immune-Onc Therapeutics in the Palo Alto ecosystem

Live from Dealroom

The Immune-Onc Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A11 investors entered at this stage

  • CLI Ventures
  • Loyal Valley Capital
  • NLVC
  • Vivo Capital
  • The Leukemia & Lymphoma Society
  • Sphera Funds Management
  • Octagon Capital Partners
  • Oceanpine Capital
  • Proxima Ventures
  • WuXi Biologics
  • TriWise Capital

Other known investors1 additional known investor

  • The University of Texas Southwestern Medical School
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States80%
🇨🇳 China20%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Immune-Onc Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immune-Onc Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.